

## EVENT SPONSORSHIP AGREEMENT

This sponsorship agreement (“**Agreement**”) is effective as of the November 27, 2022 (“**Effective Date**”) and is entered by and between:

**BeiGene Sweden AB**, a Swedish liability company, with its registered address at c/o Convendum, Gävlegatan 16, 113 30, Stockholm, Sweden (“**BeiGene**”)

and

**LYLE** (Patient Advocacy Group for Lymphoma, Leukemia and MDS), Banetoften 26, 4700 Næstved, Denmark. (“**Recipient**”)

**WHEREAS**, BeiGene is a biotechnology company that develops and commercializes biopharmaceutical products;

**WHEREAS** Recipient is a non-for profit or profit organization that wish to organize the event described in Article 1 of the Agreement and has requested funding support.

**WHEREAS** BeiGene after receiving Recipient request, which is attached as annex 1, has agreed to provide support to the Event as described below.

**NOW THEREFORE** in connection therewith and in consideration thereof, Recipient and BeiGene agree as follows:

1. BeiGene will provide Recipient with two hundred fifty-two thousand five hundred, 252,500 DKK (“**Support**”) which shall be used by Recipient for the event described in this Article 1 (“**Event**”) and BeiGene will receive the sponsorship benefits described in this Article 1.

### **Event Details**

**Title of Event:** Nordic Blood Cancer Council meeting

**Date of Event:** TBD – Autumn 2022

**Location of Event:** Stockholm, Sweden

Agenda of the Event is attached as annex 2 to this Agreement.

### **Sponsorship Benefits**

BeiGene will be entitled to the following sponsorship benefits: Possibility to support patient organisations in the Nordics to meet and share best practices in their work for patients.

2. Payment of the Support shall be made by BeiGene to the bank account of Recipient identified on the invoice received from Recipient within forty-five (45) days. The invoices must display any applicable VAT amount separately.
3. Recipient shall transparently disclose that BeiGene has provided Support for the Event. BeiGene shall have the right to publish the name of Recipient and the details of the Support and Event in order to comply with transparency reporting requirements. Such reporting may include the name of any relevant healthcare professional (HCP) who was a presenter at the Event and was paid at fair market value for his or her contribution to the Event.

4. BeiGene shall have no control or influence over the Event of the Event. BeiGene does not agree, recommend, obtain or otherwise provide any details of the attendees that will participate in the Event.
5. The Parties agree that the sponsorship is not being provided by BeiGene, nor accepted by Recipient, as an inducement to, either now or in the future, purchase, prescribe, promote, or recommend any of BeiGene's products or services.
6. No part of the Support may be paid to any third party, other than as reasonable fair market value compensation for items and services obtained at fair market value provided to Recipient in connection with the Event in accordance with applicable laws, regulations and applicable industry codes of practice (including those pertaining to transparency reporting).
7. No portion of the Support shall be used by the Recipient to provide unlawful benefits to a healthcare professional or to any government employee or official. The Recipient represents and warrants that no person or company working on behalf of the Recipient, shall directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any person or entity for the purposes of obtaining or retaining business or any improper advantage in connection with this Agreement, or that would otherwise violate any applicable laws, rules and regulations concerning or relating to public or commercial bribery or corruption.  
Recipient agrees to comply with all the regulations relating to Anti-Bribery, including the United States Foreign Corrupt Practices Act, as amended from time to time, with regard to the Event including not offering or giving anything of value to a foreign public official in connection with the performance of the official's duties or inducing an official to use their position to influence any acts or decisions of any foreign, state or public international organization.  
Additionally, Recipient agrees to comply with the UK Antibribery Act.
8. The Recipient is free to seek funding from other companies. If any additional funding reaches a level such that all or part of the Support is no longer required by the Recipient, the Recipient shall refund such amount of the Support that is no longer required. Recipient shall return any unused funds provided by BeiGene or any amounts not used in accordance with the terms and conditions of this Agreement:
  - within 30 days from the date of the Event or;
  - within 30 days from the cancellation of the Event or;
  - within 30 days from termination by BeiGene of the Agreement for Recipient breach of the obligations contained in the Agreement.
9. Any discussion of medicinal therapies or test/quizzes/votes concerning Continuing Professional Development (CPD) at the Event shall be non-promotional, balanced, accurate and complete and shall comply with applicable laws and regulations
10. The Event shall be attended by healthcare professionals only



11. Recipient confirms that the selection of the location and timing of the Event is based on one of the following criteria: (i) the majority of the attendees are resident in the country where the Event will take place, or (ii) the attendees at the Event are coming from different countries and, therefore, the Event was selected based on logistical convenience considering the country of residence of the attendees.
12. In the event Recipient becomes aware of an adverse event and/or a product complaint, Recipient shall inform BeiGene's Safety Operations Group within 24 hours of first becoming aware via [adverse\\_events@beigene.com](mailto:adverse_events@beigene.com) and/or [productcomplaints@beigene.com](mailto:productcomplaints@beigene.com).
13. If attendees require proof of attendance to the Event, the Recipient is solely responsible for providing such proof and/or CPD education records, and shall comply with all applicable data privacy law requirements and necessary consents (and any transparency disclosures as contemplated under section 3 of this Agreement) to process such requests, including but not limited to ensuring the Event qualifies as a recognised course and is code compliant with the relevant medical association, where applicable.
14. Recipient shall keep and maintain until ten (10) years after the Event have been completed full and accurate records relating to (i) the Event and the Support; (ii) all expenditure reimbursed by the Recipient; and (iii) all payments to any third party (HCPs included) made by the Recipient in connection with this Agreement. To ensure compliance with any applicable laws and regulations by BeiGene, Recipient shall promptly on request afford BeiGene or BeiGene's representatives' access to all records relating to (i), (ii) and (iii) above at BeiGene's expenses. Such records shall be made available to BeiGene during normal business hours at the Recipient's office or place of business or, in the event that no such location is reasonably available, via email.
15. The Parties will process all personal data (as defined in applicable data protection laws) obtained during the course of the Event in accordance with the applicable data protection laws.

BeiGene will only process any personal data received from the Recipient in order to enter into or perform this Agreement. Recipient warrants that it shall limit the personal data disclosed to BeiGene to the contact information for individuals involved with this Agreement and shall inform or obtain the prior written consent of each individual, as required by applicable law, for the disclosure of their respective personal data to BeiGene and processing in accordance with this clause. The parties understand that BeiGene will not have any further information/consent obligations towards the Recipient's personnel.

16. This Agreement shall commence on the Effective Date and shall automatically terminate two (2) months from the date of the completion of the Event.
17. In the event of a conflict between the provisions in the main body of this Agreement and any annex or attachment hereto, the provisions of this Agreement will control.
18. The parties agree that this Agreement will be governed by and interpreted under the laws of Denmark. Any dispute arising out of this Agreement shall be submitted to the exclusive jurisdiction of the competent courts of Copenhagen, Denmark.

19. This Agreement may be executed in counterparts all of which taken together shall constitute one agreement and copies may be exchanged electronically, such as by e-mail (e.g. PDF) and such electronic copy of the signed document will be considered valid and binding on the signing Party.

**BeiGene Sweden AB**

DocuSigned by:  
  
 Signer Name: Carl-Gustav Fabiansson  
Signing Reason: I approve this document  
Signing Time: 11-Oct-2022 | 02:50:16 PDT  
AD5253FA6BBA4BE59EEBA0E6B0384D09



---

Name (CAPS): Carl-Gustav Fabiansson

Title: Senior Director, Country Manager Nordics

Date:

**LYLE (Patient Advocacy Group for Lymphoma, Leukemia and MDS)**

DocuSigned by:  
  
 Signer Name: Rita O. Christensen  
Signing Reason: Jeg godkender dette dokument  
Signing Time: 12-okt-2022 | 06:19:44 PDT  
533EC4F9950A4CED9A984D1B0E512FDA

---

Name (CAPS): Rita O. Christensen

Title: Formand

Date:

**Annex 1 - Original Request for Support/Sponsorship Benefits**

Patient Advocacy Group for  
Lymphoma, Leukemia and MDS



Beigene Denmark  
Att: Henrik Hauerholt

14<sup>th</sup> of May 2020

On behalf of LYLE – Organisation for Lymphoma, Leukemia and MDS patients - dedicated to support patients with Blood cancer (and their relatives), we would like to request for support for the next **Nordic Blood Cancer Council meeting** in Stockholm. For detailed information please see attached [decription](#).

The objectives are:

- *Finding common grounds for the Nordics on a HTA level*
- *Early Diagnostics*
- *Spotting mutations in an early stage*
- *Targeted medicine as a first line treatment*
- *QoL issues as part of PRO's*

A broad wish for Nordic Blood Cancer Council is:

- *Equal access to medicine in the Nordics –show the value/cost of treatment with RWD*
- *Planning the work with early diagnosis issues*
- *PRO – different use in all countries. Could a Nordic PRO-model for each type of blood cancer disease be beneficial? MPN has project in SE, CML Advocacy Network has done a QoL questionnaire - using for inspiration for a Nordic PRO measurement tool.*
- *Patient support programs –to secure better programs for all patients with blood cancer*
- *Clinical trials –to secure patient friendly information that patient organizations has approved and to create or communicate databases to find/apply for trials*
- *Mutational testing and MRD –needing for a Nordic point of view/statement based on guidelines*

Budget Overview: A detailed budget overview is attached, which included Danish VAT.

According to local law the amount does include VAT. The amount can be transferred by convenience.

Account name LYLE – patientforeningen for Lymfekræft, Leukæmi og MDS  
Account number 1551 102 83 701  
Bank name Danske Bank  
Bank address Holmens Kanal 2, 1094 Copenhagen K  
IBAN Number DK 183 000 001 028 3701  
Swift Code DABADKKK

This support will be provided as a financial support  
Thank you in advance for your consideration of this request.

Sincerely,

---

Rita O. Christensen  
Chairwoman  
LYLE Patient organization for Lymphoma, Leukemia and MDS  
Address: Banetoften 26, DK-4700 Naestved  
Phone: +45 31 68 26 00  
E-mail: [formand@lyle.dk](mailto:formand@lyle.dk)

## Annex 2 - Agenda

### AGENDA – NBCC Meeting Stockholm Autumn 2022

*Moderator: Camille Aulkær Andersen – Kompas*

#### First day

- 14.00**            **Welcome and introduction**  
*Speaker-???*
- 14.15 – 15.30**    **The Board and goals for the NBCC**
- *The board is confirmed – Sweden, Finland, Denmark and Island*
  - *Definition of ~~Nadja's~~ ~~role~~*
  - *How can we get Norway into the Council? Anything new?*
  - *Status on financing future meetings in the NBCC and ~~Nadja's~~ ~~help~~*
- 15.30 – 16.00**    **Coffee break**
- 16.00 – 16.45**    **Exchanging informations - from each country - since the last meeting**
- *...we need a definition for this, but we can start with some of the objectives*
- 16.45 – 18.00**    **Summary and status/conclusions of earlier meetings in the Nordic:**
- *Conclusions from the meeting today*
- 18.00 – 18.30**    **Break**
- 18.30 – 22.00**    **Dinner**

#### Next day

- 09.00 – 10.30**    **Objectives for the Board and the Nordics \***
- *Equal access to medicine in the Nordics –show the value/cost of treatment with RWD*
  - *Planning the work with early diagnosis issues*
  - *PRO – different use in all countries. Could a Nordic PRO-model for each type of blood cancer disease be beneficial? MPN has project in SE, CML Advocacy Network has done a QoL questionnaire - using for inspiration for a Nordic PRO measurement tool.*
  - *Patient support programs –to secure better programs for all patients with blood cancer*
  - *Clinical trials –to secure patient friendly information that patient organizations has approved and to create or communicate databases to find/apply for trials*
  - *Mutational testing and MRD –needing for a Nordic point of view/statement based on guidelines*
- 10.30 – 11.00**            **Coffee Break**
- 11.00 – 12.00**            **Summary Speaker: Moderator**
- 12.30 – 13.30**            **Lunch and goodbye**

\* Some of the issues from this day can be moved to the first day.